BioArctic AB (publ) (BRCTF)
USD 19.71
(0.0%)
USD 19.71
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -606.58 Million SEK | 23.73% |
| 2022 | -795.34 Million SEK | 4.47% |
| 2021 | -832.52 Million SEK | 14.98% |
| 2020 | -979.17 Million SEK | 9.79% |
| 2019 | -1.08 Billion SEK | -18.33% |
| 2018 | -917.3 Million SEK | 17.39% |
| 2017 | -1.11 Billion SEK | -60.33% |
| 2016 | -692.53 Million SEK | -508.38% |
| 2015 | -113.83 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -429.97 Million SEK | 11.66% |
| 2024 Q1 | -486.71 Million SEK | 19.76% |
| 2023 Q3 | -694.73 Million SEK | 32.94% |
| 2023 Q1 | -1.09 Billion SEK | -38.06% |
| 2023 FY | -606.58 Million SEK | 23.73% |
| 2023 Q2 | -1.03 Billion SEK | 5.65% |
| 2023 Q4 | -606.58 Million SEK | 12.69% |
| 2022 Q1 | -786.68 Million SEK | 5.51% |
| 2022 Q4 | -795.34 Million SEK | 6.76% |
| 2022 Q2 | -739.55 Million SEK | 5.99% |
| 2022 FY | -795.34 Million SEK | 4.47% |
| 2022 Q3 | -852.99 Million SEK | -15.34% |
| 2021 FY | -832.52 Million SEK | 14.98% |
| 2021 Q4 | -832.52 Million SEK | 4.71% |
| 2021 Q3 | -873.71 Million SEK | 4.02% |
| 2021 Q2 | -910.33 Million SEK | 3.26% |
| 2021 Q1 | -941.03 Million SEK | 3.89% |
| 2020 Q2 | -1.02 Billion SEK | 2.44% |
| 2020 Q3 | -1.01 Billion SEK | 1.24% |
| 2020 Q4 | -979.17 Million SEK | 3.46% |
| 2020 FY | -979.17 Million SEK | 9.79% |
| 2020 Q1 | -1.05 Billion SEK | 3.02% |
| 2019 Q4 | -1.08 Billion SEK | 4.93% |
| 2019 Q2 | -1.18 Billion SEK | 2.91% |
| 2019 Q1 | -1.22 Billion SEK | -33.44% |
| 2019 Q3 | -1.14 Billion SEK | 3.93% |
| 2019 FY | -1.08 Billion SEK | -18.33% |
| 2018 FY | -917.3 Million SEK | 17.39% |
| 2018 Q4 | -917.3 Million SEK | 9.04% |
| 2018 Q2 | -1.04 Billion SEK | 3.43% |
| 2018 Q1 | -1.07 Billion SEK | 2.85% |
| 2018 Q3 | -1 Billion SEK | 3.19% |
| 2017 FY | -1.11 Billion SEK | -60.33% |
| 2017 Q1 | 692.53 Million SEK | 200.0% |
| 2017 Q2 | -622.06 Million SEK | -189.82% |
| 2017 Q3 | -590.67 Million SEK | 5.05% |
| 2017 Q4 | -1.11 Billion SEK | -87.98% |
| 2016 FY | -692.53 Million SEK | -508.38% |
| 2016 Q1 | 113.83 Million SEK | 0.0% |
| 2016 Q4 | -692.53 Million SEK | 0.0% |
| 2015 FY | -113.83 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 3948.176% |
| SQZ Biotechnologies Company | -36.23 Million USD | -1573.9% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 27152.853% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 1517.494% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -9521.472% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 65522.472% |
| Mesoblast Limited | 55.85 Million USD | 1185.942% |
| Marizyme, Inc. | 18.56 Million USD | 3366.665% |
| Genus plc | 190.6 Million USD | 418.252% |
| Pharming Group N.V. | 109.8 Million USD | 652.428% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 70613.728% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 50070.673% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 89304.118% |
| ContraFect Corporation | -6.02 Million USD | -9966.18% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 52598.942% |
| IMV Inc. | 7.67 Million USD | 8008.042% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 11125.072% |
| MultiCell Technologies, Inc. | 90.04 USD | 673687350.111% |
| ONE Bio Corp. | 9.04 Million USD | 6810.018% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 4785.524% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 2085.298% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 97565.149% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 60294.34% |
| Biomind Labs Inc. | 711.4 Thousand USD | 85366.558% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 30438.623% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 4836.53% |
| Skye Bioscience, Inc. | -5.72 Million USD | -10502.111% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 168732.51% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 433984.581% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 10839.169% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 3053344.073% |
| GB Sciences, Inc. | 1.74 Million USD | 34815.415% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -329947.664% |
| CSL Limited | 10.52 Billion USD | 105.763% |
| Agentix Corp. | 37.63 Thousand USD | 1612036.967% |
| Enzolytics Inc. | 981.65 Thousand USD | 61892.318% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -90020.029% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 70.102% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 1496.574% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -1190.283% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 8678.566% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -6761.924% |
| Zenith Capital Corp. | 10.06 Thousand USD | 6027405.246% |
| Genscript Biotech Corporation | -1.06 Billion USD | 42.847% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 14830.074% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 151049.237% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 25522.437% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 368826.331% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -3311331.379% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 27230.303% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 450629.193% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -82543.894% |
| Helix BioMedix, Inc. | -2.57 Million USD | -23502.352% |
| EV Biologics, Inc. | 1.36 Million USD | 44442.168% |
| Q BioMed Inc. | 4.06 Million USD | 15040.562% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 3091.655% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 1101.867% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | 4.47 Million USD | 13664.099% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 27647.377% |
| HST Global, Inc. | 96.79 Thousand USD | 626785.814% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -46304327.481% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 294250.337% |
| Halberd Corporation | 144.72 Thousand USD | 419243.041% |
| Resverlogix Corp. | 6.45 Million USD | 9503.007% |
| Cell Source, Inc. | 9.23 Million USD | 6670.515% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -2972204.978% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 95600.553% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 22494.766% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -10175.567% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 302740.297% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | 2.17 Million USD | 27944.744% |
| Kadimastem Ltd | -253.1 Thousand USD | -239561.48% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 446156.666% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 301504.196% |
| LadRx Corporation | -2.03 Million USD | -29686.262% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 95600.553% |
| Affymax, Inc. | -5.59 Million USD | -10737.735% |
| Itoco Inc. | 228.3 Thousand USD | 265791.947% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 12336.998% |
| Mobile Lads Corp. | 484.23 Thousand USD | 125368.053% |
| CytoDyn Inc. | 20.26 Million USD | 3093.722% |
| International Stem Cell Corporation | 2.59 Million USD | 23520.386% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | 1.89 Million USD | 32043.943% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -93753841.267% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -6544631.851% |
| Qrons Inc. | 351.42 Thousand USD | 172707.113% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 7971.63% |
| SYBLEU INC | 473.71 Thousand USD | 128149.414% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -242904.567% |
| Rebus Holdings, Inc. | 305 Thousand USD | 198981.311% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 13709.715% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 971993.676% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 27913.655% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 17764.182% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 7192.108% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 78611.844% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -48427.04% |
| Neutra Corp. | 52.18 Thousand USD | 1162435.448% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -24270.751% |
| PureTech Health plc | -167.19 Million USD | -262.798% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -247579.945% |
| IXICO plc | -4.44 Million USD | -13547.792% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 4688.759% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 1205.883% |
| CSL Limited | 10.52 Billion USD | 105.763% |
| Cellectis S.A. | -43.81 Million USD | -1284.308% |